Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com

StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Trading Down 30.4 %

NASDAQ CYCC opened at $1.60 on Wednesday. Cyclacel Pharmaceuticals has a 1-year low of $1.41 and a 1-year high of $13.20. The company has a market capitalization of $2.11 million, a PE ratio of -0.06 and a beta of 0.54. The firm’s fifty day simple moving average is $2.31 and its 200-day simple moving average is $3.85.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.35) by $0.12. The company had revenue of $0.03 million during the quarter. As a group, analysts predict that Cyclacel Pharmaceuticals will post -18.7 EPS for the current year.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.